Vor Biopharma Company Insiders
| VOR Stock | USD 1.01 0.03 2.88% |
Vor Biopharma employs about 168 people. The company is managed by 14 executives with a total tenure of roughly 392 years, averaging almost 28.0 years of service per executive, having 12.0 employees per reported executive. Discussion of Vor Biopharma's management performance can provide insight into the enterprise performance.
Vor |
Vor Biopharma Management Team Effectiveness
The company has Return on Asset of (0.3974) % which means that on every $100 spent on assets, it lost $0.3974. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7807) %, meaning that it generated no profit with money invested by stockholders. Vor Biopharma's management efficiency ratios could be used to measure how well Vor Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/11/2024, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to drop to -0.72. As of 12/11/2024, Net Tangible Assets is likely to grow to about 302.6 M, while Total Assets are likely to drop slightly above 151.6 M.As of 12/11/2024, Common Stock Shares Outstanding is likely to drop to about 41 M. In addition to that, Net Loss is likely to grow to about (78.7 M)
Vor Biopharma Workforce Comparison
Vor Biopharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,366. Vor Biopharma holds roughly 168 in number of employees claiming about 5% of equities under Health Care industry.
Vor Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vor Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vor Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vor Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ang Robert over a week ago Acquisition by Ang Robert of 150000 shares of Vor Biopharma subject to Rule 16b-3 | ||
Ang Robert over two weeks ago Disposition of 2788 shares by Ang Robert of Vor Biopharma at 2.32 subject to Rule 16b-3 | ||
Ang Robert over a month ago Disposition of 2361 shares by Ang Robert of Vor Biopharma at 0.86 subject to Rule 16b-3 | ||
Ang Robert over a month ago Disposition of 2751 shares by Ang Robert of Vor Biopharma at 0.8 subject to Rule 16b-3 | ||
Jorgensen Nathan D. over a month ago Acquisition by Jorgensen Nathan D. of 91000 shares of Vor Biopharma at 5.55 subject to Rule 16b-3 | ||
Ang Robert over a month ago Disposition of 2361 shares by Ang Robert of Vor Biopharma at 0.87 subject to Rule 16b-3 | ||
Choi Han Wook over a month ago Acquisition by Choi Han Wook of 400000 shares of Vor Biopharma at 0.7 subject to Rule 16b-3 | ||
Resnick Joshua over two months ago Acquisition by Resnick Joshua of 16911 shares of Vor Biopharma at 4.26 subject to Rule 16b-3 |
Vor Biopharma Notable Stakeholders
A Vor Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vor Biopharma often face trade-offs trying to please all of them. Vor Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vor Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| PharmD D | Chief Officer | Profile | |
| Samir MS | Senior Management | Profile | |
| Han MD | Chief Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Eyal MD | Chief Officer | Profile | |
| Tania Philipp | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile | |
| Pharm PharmD | Chief Officer | Profile | |
| Amy Quinlan | Interim Officer | Profile | |
| Veit Schmelmer | VP Management | Profile | |
| John MBA | Chief Development | Profile | |
| David MBA | Senior Quality | Profile | |
| Tirtha Chakraborty | Chief Officer | Profile | |
| DPHIL MD | Scientific Board | Profile |
About Vor Biopharma Management Performance
The success or failure of an entity such as Vor Biopharma often depends on how effective the management is. Vor Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vor management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vor management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.78) | (0.82) |
Vor Biopharma Workforce Analysis
Traditionally, organizations such as Vor Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vor Biopharma within its industry.Vor Biopharma Manpower Efficiency
Return on Vor Biopharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 701.6K | |
| Net Loss Per Executive | 8.4M | |
| Working Capital Per Employee | 745.4K | |
| Working Capital Per Executive | 8.9M |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.